Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells

Open access
Delgado-Goñi, Teresa, Galobart, Teresa Casals, Wantuch, Slawomir, Normantaite, Deimante, Leach, Martin O., Whittaker, Steven R., Beloueche-Babari, Mounia · 2020 · British Journal of Cancer

Abstract

Background: BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF -mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational strategies for combinatorial treatment. Methods: This work investigates the metabolic characteristics and vulnerabilities of acquired resistance to vemurafenib in three generated BRAF -mutant human melanoma cell clones, analysing metabolic profiles, gene and protein expression in baseline and nutrient withdrawal conditions. Preclinical findings are correlated with gene expression analysis from publicly available clinical datasets. Results: Two vemurafenib-resistant clones showed dependency on lipid metabolism and increased prostaglandin E2 synthesis and were more responsive to vemurafenib under EGFR inhibition, potentially implicating inflammatory lipid and EGFR signalling in ERK reactivation and vemurafenib resistance. The third resistant clone showed higher pyruvate-carboxylase (PC) activity indicating increased anaplerotic mitochondrial metabolism, concomitant with reduced GLUT-1, increased PC protein expression and survival advantage under nutrient-depleted conditions. Prostaglandin synthase ( PTGES ) expression was inversely correlated with melanoma patient survival. Increases in PC and PTGES gene expression were observed in some patients following progression on BRAF inhibitors. Conclusions: Altogether, our data highlight heterogeneity in metabolic adaptations during acquired resistance to vemurafenib in BRAF -mutant melanoma, potentially uncovering key clinically-relevant mechanisms for combinatorial therapeutic targeting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-019-0628-x

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Metabolomic profiling identifies decreased metabolic activity in BRAF-inhibitor-resistant clones. a A bi-dimensional PLS-DA score scatter plot showing separate clustering for the sensitive and the resistant clones. b Heterogeneity between the three vemurafenib-resistant clones as represented in the score scatter plot. c The separation between all the resistant cells, considered as one group, and the sensitive cells. d The panel represents a score contribution plot with corresponding changes in the 1H NMR peaks (and related metabolites shown in the representative spectrum below) accounting for the differences between sensitive and resistant clones (plot obtained using the Group to Group comparison option in SIMCA). Positive scores represent increased levels while negative scores indicate decreased levels in sensitive relative to resistant cells. Those variables considered as the most relevant for group separation had a contribution coefficient ≥ |2|.
Fig. 1 Metabolomic profiling identifies decreased metabolic activity in BRAF-inhibitor-resistant clones. a A bi-dimensional PLS-DA score scatter plot showing separate clustering for the sensitive and the resistant clones. b Heterogeneity between the three vemurafenib-resistant clones as represented in the score scatter plot. c The separation between all the resistant cells, considered as one group, and the sensitive cells. d The panel represents a score contribution plot with corresponding changes in the 1H NMR peaks (and related metabolites shown in the representative spectrum below) accounting for the differences between sensitive and resistant clones (plot obtained using the Group to Group comparison option in SIMCA). Positive scores represent increased levels while negative scores indicate decreased levels in sensitive relative to resistant cells. Those variables considered as the most relevant for group separation had a contribution coefficient ≥ |2|.CC BY · PubMed Central
Fig. 2 Schematic representation of the main metabolic routes investigated by nutrient withdrawal in sensitive and resistant cells. Glucose, glutamine, pyruvate and lipids were depleted from the media and the metabolic and molecular responses induced in the cells were characterised. GLUT-1, glucose transporter; PGE2, prostaglandin E2.
Fig. 2 Schematic representation of the main metabolic routes investigated by nutrient withdrawal in sensitive and resistant cells. Glucose, glutamine, pyruvate and lipids were depleted from the media and the metabolic and molecular responses induced in the cells were characterised. GLUT-1, glucose transporter; PGE2, prostaglandin E2.CC BY · PubMed Central
Fig. 3 Resistance to BRAF inhibition is associated with a greater dependency on lipids and EGFR signalling. a GI50 values for vemurafenib in the 4 clones growing under 10 and 1% lipid media. B4 and D9 clones become more sensitive to the drug under lipid-depletion. b On the left, mRNA expression of COX-1 and mPTGES-1 in the three resistant clones and treated (2 µM vemurafenib) sensitive cells with respect to the parental clone A375. On the right, protein expression levels of PGE2 and MAPK related proteins in a representative replicate of the four clones under standard media conditions. c Extracellular PGE2 excretion after 24 h of fresh media addition in the four clones (% with respect to A375-sensitive cells). d GI50 values for vemurafenib in the four clones when combined with 6 µM gefitinib. *p < 0.05, **p < 0.01.
Fig. 3 Resistance to BRAF inhibition is associated with a greater dependency on lipids and EGFR signalling. a GI50 values for vemurafenib in the 4 clones growing under 10 and 1% lipid media. B4 and D9 clones become more sensitive to the drug under lipid-depletion. b On the left, mRNA expression of COX-1 and mPTGES-1 in the three resistant clones and treated (2 µM vemurafenib) sensitive cells with respect to the parental clone A375. On the right, protein expression levels of PGE2 and MAPK related proteins in a representative replicate of the four clones under standard media conditions. c Extracellular PGE2 excretion after 24 h of fresh media addition in the four clones (% with respect to A375-sensitive cells). d GI50 values for vemurafenib in the four clones when combined with 6 µM gefitinib. *p < 0.05, **p < 0.01.CC BY · PubMed Central
Fig. 4 Vemurafenib-resistant cell clones exhibit decreased glycolytic metabolism and enhanced mitochondrial anaplerotic metabolism. a Resistant R6 cells produce significantly less lactateE and show a significantly lower glucose uptake in comparison to A375 cells. b R6 cells produce significantly less glutamate ([4]-[4,5] glutamate) than sensitive cells but maintain similar fumarate and acetate levels despite a lower glucose consumption rate, indicating a potential upregulation in TCA activity non-glutamine or PDH dependent. Anaplerotic TCA activity is significantly higher in R6 cells compared to the parental clone (p = 0.01). c The molecular analysis of three biological replicates from A375 and R6 cells revealed a lower GLUT-1 and GLS (KGA and GAC isoforms) expression and a higher PC expression in vemurafenib-resistant cells in comparison to sensitive cells. **p < 0.01.
Fig. 4 Vemurafenib-resistant cell clones exhibit decreased glycolytic metabolism and enhanced mitochondrial anaplerotic metabolism. a Resistant R6 cells produce significantly less lactateE and show a significantly lower glucose uptake in comparison to A375 cells. b R6 cells produce significantly less glutamate ([4]-[4,5] glutamate) than sensitive cells but maintain similar fumarate and acetate levels despite a lower glucose consumption rate, indicating a potential upregulation in TCA activity non-glutamine or PDH dependent. Anaplerotic TCA activity is significantly higher in R6 cells compared to the parental clone (p = 0.01). c The molecular analysis of three biological replicates from A375 and R6 cells revealed a lower GLUT-1 and GLS (KGA and GAC isoforms) expression and a higher PC expression in vemurafenib-resistant cells in comparison to sensitive cells. **p < 0.01.CC BY · PubMed Central
Fig. 5 A decreased dependency on glucose, glutamine and pyruvate is observed in vemurafenib-resistant cells. a Cell numbers after 72 h of seeding A375 and R6 cells in different nutrient conditions. b Cell numbers in both A375 and R6 clones after 72 h growing in 1 mM glucose media with 2 µM vemurafenib for the last 24 h, compared to DMSO-treated cells growing in the same glucose conditions. c TCA-related protein expression in control and treated samples (2 µM vemurafenib) from both clones in 25 or 1 mM conditions. d GI50 curves for R6 2D and 3D cell cultures with vemurafenib in 25 mM or 1 mM glucose media. *p < 0.05, **p < 0.01.
Fig. 5 A decreased dependency on glucose, glutamine and pyruvate is observed in vemurafenib-resistant cells. a Cell numbers after 72 h of seeding A375 and R6 cells in different nutrient conditions. b Cell numbers in both A375 and R6 clones after 72 h growing in 1 mM glucose media with 2 µM vemurafenib for the last 24 h, compared to DMSO-treated cells growing in the same glucose conditions. c TCA-related protein expression in control and treated samples (2 µM vemurafenib) from both clones in 25 or 1 mM conditions. d GI50 curves for R6 2D and 3D cell cultures with vemurafenib in 25 mM or 1 mM glucose media. *p < 0.05, **p < 0.01.CC BY · PubMed Central
Fig. 6 Elevated expression of PTGES/PTGES2 is associated with poor survival of melanoma patients and acquired resistance to BRAF inhibition. a Overall survival in 469 patients affected by melanoma tumours with or without genetic alterations (amplification or mRNA overexpression) in the PTGES or PTGES2 genes. Alterations in PTGES or PTGES2 (red line, z-score > 2) correlated with a significantly lower survival (p = 0.0045). b Expression of PTGES, PTGES2 and PC mRNA in pre-treatment and post-progression tumour biopsies from melanoma patients treated with vemurafenib or dabrafenib (red lines and symbols indicate increased expression in the post-progression biopsy relative to the pre-treatment biopsy).
Fig. 6 Elevated expression of PTGES/PTGES2 is associated with poor survival of melanoma patients and acquired resistance to BRAF inhibition. a Overall survival in 469 patients affected by melanoma tumours with or without genetic alterations (amplification or mRNA overexpression) in the PTGES or PTGES2 genes. Alterations in PTGES or PTGES2 (red line, z-score > 2) correlated with a significantly lower survival (p = 0.0045). b Expression of PTGES, PTGES2 and PC mRNA in pre-treatment and post-progression tumour biopsies from melanoma patients treated with vemurafenib or dabrafenib (red lines and symbols indicate increased expression in the post-progression biopsy relative to the pre-treatment biopsy).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 39

Metadata

Authors
Delgado-Goñi, T., Galobart, T. C., Wantuch, S., Normantaite, D., Leach, M. O., Whittaker, S. R., & Beloueche-Babari, M.
Affiliations
  • Royal Marsden NHS Foundation Trust (GB)
  • Institute of Cancer Research (GB)
Corresponding author
Leach, Martin O.
Venue
British Journal of Cancer
Published
2019-12-10
Volume
122
Issue
1
Pages
72-81
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2993997447
Cited by
39
References
52
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 7 · 2019: 1
FWCI
1.48
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • RCUK | Medical Research Council (MR/K011057/1)
  • Cancer Research UK (C1060/A10334, C1090/A16464)
  • Start-up funds from The Institute of Cancer Research.
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
vemurafenib resistance, BRAF-mutant melanoma, acquired drug resistance, prostaglandin E2 synthesis, prostaglandin E synthase, pyruvate carboxylase, anaplerotic metabolism, mitochondrial metabolism, EGFR inhibition, GLUT1, metabolic vulnerability
MeSH terms
Prostaglandin-E Synthases, Gefitinib, Vemurafenib, Antineoplastic Agents, Cell Survival, Humans, Melanoma, Mitochondria, Mutation, Pyruvate Carboxylase, Skin Neoplasms, Dinoprostone, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. https://app.cochat.ai/papers/10.1038/s41416-019-0628-x
The paper
Delgado-Goñi, T., Galobart, T. C., Wantuch, S., Normantaite, D., Leach, M. O., Whittaker, S. R., & Beloueche-Babari, M. (2020). Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0628-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.